128 related articles for article (PubMed ID: 24707258)
1. Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer.
Yoshida Y; Hoshino S; Aisu N; Naito M; Tanimura S; Sasaki T; Takeno S; Yamashita Y
Case Rep Oncol; 2014 Jan; 7(1):117-21. PubMed ID: 24707258
[TBL] [Abstract][Full Text] [Related]
2. Early start of chemotherapy after resection of brain metastasis from colon cancer with synchronous multiple liver metastases.
Yoshida Y; Hoshino S; Miyake T; Fukuda S; Yamada K; Naoya A; Tanimura S; Yamashita Y
Case Rep Oncol; 2012 May; 5(2):290-5. PubMed ID: 22740818
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report.
Ibrahimi AK; Al-Hussaini M; Laban DA; Ammarin R; Wehbeh L; Al-Mousa A
CNS Oncol; 2023 Jun; 12(2):CNS97. PubMed ID: 37129184
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
5. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer.
Uchima Y; Nishii T; Iseki Y; Ishii M; Hiramatsu S; Iwauchi T; Morimoto J; Kosaka K; Tei S; Takeuchi K
Mol Clin Oncol; 2014 Jan; 2(1):134-138. PubMed ID: 24649322
[TBL] [Abstract][Full Text] [Related]
7. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Hurwitz H; Mitchell EP; Cartwright T; Kwok A; Hu S; McKenna E; Patt YZ
Oncologist; 2012; 17(7):937-46. PubMed ID: 22622147
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
9. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Int J Clin Oncol; 2010 Jun; 15(3):256-62. PubMed ID: 20198398
[TBL] [Abstract][Full Text] [Related]
10. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
Matsui T; Nagata N; Hirata K; Okazaki S; Sato S; Nakamura M; Kim H; Oba K; Sakamoto J; Mishima H
Anticancer Res; 2016 Jul; 36(7):3437-43. PubMed ID: 27354605
[TBL] [Abstract][Full Text] [Related]
11. A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.
Kim JH; Zang DY; Chung IJ; Cho SH; Park KU; Oh HS; Lee KH; Lee BH; Kim MJ; Park CK; Han B; Kim HS; Choi DR; Song HH; Jung JY
J Cancer; 2015; 6(10):1041-8. PubMed ID: 26366218
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S; Li J; Bai Y; Shu Y; Li W; Yin X; Cheng Y; Sun G; Deng Y; Zhong H; Li Y; Qian X; Zhang L; Zhang J; Chen K; Kang W;
BioDrugs; 2021 Jul; 35(4):445-458. PubMed ID: 34014555
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Vamvakas L; Matikas A; Karampeazis A; Hatzidaki D; Kakolyris S; Christophylakis C; Boukovinas I; Polyzos A; Georgoulias V; Souglakos J
BMC Cancer; 2014 Apr; 14():277. PubMed ID: 24755296
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
[TBL] [Abstract][Full Text] [Related]
18. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
Tyagi P; Grothey A
Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510
[TBL] [Abstract][Full Text] [Related]
19. A Complete Response Case in a Patient with Multiple Lung Metastases of Rectal Cancer Treated with Bevacizumab plus XELIRI Therapy.
Hashida H; Satake H; Kaihara S
Case Rep Oncol; 2017; 10(1):81-85. PubMed ID: 28203168
[TBL] [Abstract][Full Text] [Related]
20. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]